PeptiDream Set to Develop Peptide-RI Conjugates for Refractory Cancers, Eyes No. 1 Spot in Radiotherapy

June 20, 2022
PeptiDream CFO Kiyofumi Kaneshiro (right), PDRadiopharma President Susumu Tanahashi PeptiDream is revving up its “theranostics” business, which taps radiopharmaceuticals to integrally provide diagnostic and therapeutic solutions for cancer treatment. It aims to become the No. 1 radiotherapy player in Japan...read more